Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection
Primary Purpose
Surgical Site Infection
Status
Completed
Phase
Not Applicable
Locations
Rwanda
Study Type
Interventional
Intervention
Cefazolin
Placebos
Sponsored by
About this trial
This is an interventional health services research trial for Surgical Site Infection
Eligibility Criteria
Inclusion Criteria:
- - All elective non-prosthetic surgical procedures such as hernia, thyroid, hydrocele, undescended testes surgery, removal of orthopedic implants, low risk breast surgical procedures and other all procedures deemed to be clean.
Exclusion Criteria:
- - Emergency cases
- Any patient with American Society of Anesthesiologists Score (ASA)>2
- Procedures lasting more than 2 hours
- Patients who were taking antibiotics 2 days prior to operation
Sites / Locations
- Kigali University Teaching Hospital (Chuk)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Prophylaxis
No prophylaxis
Arm Description
The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
Outcomes
Primary Outcome Measures
Surgical site infection
surgical wounds will be accessed for signs of surgical site infection at discharge by a treating surgeon and patients will be called 30 days after operation for signs of surgical site infection
Secondary Outcome Measures
mortality
death
morbidity
morbidity will be defined as any one of the following clinical diagnoses made by a treating surgeon: unplanned reoperation, healthcare associated infection, pneumonia, cardiac arrest, pulmonary embolism
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03595852
Brief Title
Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection
Official Title
Preoperative Antibiotic Prophylaxis Versus Placebo in Clean, Non-prosthetic Surgery at CHUK. Impact on Surgical Site Infections and Patient Cost.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
September 1, 2018 (Actual)
Study Completion Date
March 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Rwanda
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized control study of antibiotic uses in clean non prosthetic surgeries. One group will be given antibiotic prophylaxis, other will receive a placebo. The primary outcome will be the rate of surgical site infection in 2 groups.
Detailed Description
I will conduct a randomized controlled trial (RCT) of antibiotic prophylaxis versus placebo in clean, non-prosthetic, elective procedures. The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg and 30mg/kg in children) within 30-60 minutes prior to skin incision. The control group will receive a similarly prepared placebo injection (water for injection) 30-60 minutes prior to incision.
I will randomize patients in a 1:1 allocation ratio using a simple randomization. Patients will randomly pick an envelope with a number allocating to antibiotic prophylaxis or placebo. Patients and caretakers will be blinded to the intervention. The surgeon will also be blinded to the intervention. The antibiotic (or placebo) will be pre-mixed by the study investigator and administered by the anesthetist.
Other preventive measures for surgical site infection (SSIs) such as effective surgical hand scrub, proper skin preparation with povidone and sterility of materials and instrument will be applied systematically in all groups. Dressing of the wound will be removed 48 hours after operation and no further dressing will be required. Patients will be followed for development of SSI documented by surgeon at discharge and will be called after 30 days of surgery to address any sign of SSI.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
antibiotic prophylaxis versus placebo in clean non prosthetic surgery. impact on surgical site infection and patient cost.
Masking
ParticipantInvestigator
Masking Description
patients and investigator will be blinded for intervention
Allocation
Randomized
Enrollment
138 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Prophylaxis
Arm Type
Experimental
Arm Description
The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
Arm Title
No prophylaxis
Arm Type
Placebo Comparator
Arm Description
The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
Intervention Type
Drug
Intervention Name(s)
Cefazolin
Other Intervention Name(s)
ancef
Intervention Description
Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
Intervention Type
Drug
Intervention Name(s)
Placebos
Other Intervention Name(s)
saline
Intervention Description
IV normal saline will be given to patients 30-60 minutes prior to incision
Primary Outcome Measure Information:
Title
Surgical site infection
Description
surgical wounds will be accessed for signs of surgical site infection at discharge by a treating surgeon and patients will be called 30 days after operation for signs of surgical site infection
Time Frame
30 days post operative
Secondary Outcome Measure Information:
Title
mortality
Description
death
Time Frame
48 hours post operation
Title
morbidity
Description
morbidity will be defined as any one of the following clinical diagnoses made by a treating surgeon: unplanned reoperation, healthcare associated infection, pneumonia, cardiac arrest, pulmonary embolism
Time Frame
48 hours post operation
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- All elective non-prosthetic surgical procedures such as hernia, thyroid, hydrocele, undescended testes surgery, removal of orthopedic implants, low risk breast surgical procedures and other all procedures deemed to be clean.
Exclusion Criteria:
- Emergency cases
Any patient with American Society of Anesthesiologists Score (ASA)>2
Procedures lasting more than 2 hours
Patients who were taking antibiotics 2 days prior to operation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
FAUSTIN NTIRENGANYA, MMed, FCS
Organizational Affiliation
fostino21@yahoo.fr
Official's Role
Study Director
Facility Information:
Facility Name
Kigali University Teaching Hospital (Chuk)
City
Kigali
Country
Rwanda
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to make IPD to other researchers
Learn more about this trial
Antibiotic Prophylaxis in Clean Surgery. Impact on Surgical Site Infection
We'll reach out to this number within 24 hrs